Summary

This article presents key results from the first Phase 3 trial of certolizumab pegol (CZP) in patients with active psoriatic arthritis (PsA). In the Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult Onset Active and PsA study [RAPID-PsA; NCT01087788], patients who were treated with CZP were twice as likely to meet the primary study endpoint of ACR20 response at Week 12 compared with those who were taking placebo.